Universe Pharmaceuticals Inc. (UPC) Revenue History
Annual and quarterly revenue from 2018 to present
UPC Revenue Over Time (2018–2025)
UPC Revenue Growth History
2 of 7 years with positive growth- FY2018 revenue growth
- N/A
- FY2019 revenue growth
- +16.5%
- FY2020 revenue growth
- -7.6%
- FY2021 revenue growth
- +56.3%
- FY2022 revenue growth
- -16.3%
- FY2023 revenue growth
- -19.5%
- FY2024 revenue growth
- -28.7%
- FY2025 revenue growth
- -22.4%
| Quarter | Revenue | YoY |
|---|---|---|
| Q4 2025 | $8.7M | -14.1% |
| Q2 2025 | $9.2M | -29.0% |
| Q4 2024 | $10.1M | -26.7% |
| Q2 2024 | $12.9M | -30.2% |
| Q4 2023 | $13.8M | -13.2% |
| Q2 2023 | $18.5M | -23.7% |
| Q4 2022 | $15.9M | -32.7% |
| Q2 2022 | $24.2M | -0.4% |
UPC Revenue Analysis (2018–2025)
Current Revenue & Growth
As of June 21, 2026, Universe Pharmaceuticals Inc. (UPC) generated trailing twelve-month (TTM) revenue of $40.9 million, reflecting significant decline in growth of -14.1% year-over-year. The most recent quarter (Q4 2025) recorded $8.7 million in revenue, down 4.9% sequentially.
Historical Growth Trajectory
UPC's 5-year compound annual growth rate (CAGR) stands at -10.3%, indicating revenue contraction over this period. The 3-year CAGR of -23.7% is below the 5-year average, signalling a growth deceleration in recent years. Universe Pharmaceuticals Inc.'s highest annual revenue of $48.0 million was recorded in 2021.
Peer Comparison
Compared to Healthcare sector peers — including HCWB (+356.2% YoY), XTLB, and NUVB (+1205.5% YoY) — UPC has underperformed the peer group in revenue growth. Compare UPC vs HCWB →
UPC Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| UPCCurrent | $41M | -14.1% | -10.3% | -16.3% | |
 HCWB | $54,232 | +356.2% | -57.9% | -20757.6% | |
 XTLB | $451,000 | - | - | -481.6% | |
 NUVB | $63M | +1205.5% | - | -338.7% | |
 CPRX | $589M | +11.7% | +37.7% | 43.8% | |
 TLPH | $28,000 | -96.3% | -65.1% | -48157.1% |
UPC Historical Revenue Data (2018–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $17.9M | -22.4% | $6.3M | 35.3% | $-2,915,919 | -16.3% |
| 2024 | $23.0M | -28.7% | $6.1M | 26.4% | $-8,019,840 | -34.8% |
| 2023 | $32.3M | -19.5% | $10.3M | 31.9% | $-3,526,774 | -10.9% |
| 2022 | $40.1M | -16.3% | $21.9M | 54.5% | $-7,019,445 | -17.5% |
| 2021 | $48.0M | +56.3% | $25.3M | 52.8% | $13.6M | 28.3% |
| 2020 | $30.7M | -7.6% | $14.1M | 45.9% | $10.3M | 33.4% |
| 2019 | $33.2M | +16.5% | $13.4M | 40.3% | $9.8M | 29.4% |
| 2018 | $28.5M | - | $13.4M | 47.0% | $9.7M | 33.9% |
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
8+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
UPC — Frequently Asked Questions
Quick answers to the most common questions about buying UPC stock.
Is UPC's revenue growth accelerating or slowing?
UPC revenue is declining -14.1% year-over-year. TTM revenue fell to $41M, contrasting with the 5-year CAGR of -10.3%. The reversal reflects either macro headwinds or company-specific challenges.
What is UPC's revenue history from 2018 to 2026?
Universe Pharmaceuticals Inc. (UPC) revenue history spans 2018 to 2026. TTM revenue as of 2026 is $41M, growing at -14.1% YoY. The 5-year CAGR is -10.3%. Complete annual and quarterly revenue figures are available on this page, including gross profit, operating income, and margin trends.
What is UPC's long-term revenue growth rate (CAGR)?
Universe Pharmaceuticals Inc.'s 5-year revenue CAGR of -10.3% reflects the variable nature of its business expansion. As of 2026, the current YoY growth rate of -14.1% is below this long-term average. CAGR is the most reliable measure of sustained revenue momentum for UPC.
Why does UPC's quarterly revenue fluctuate?
UPC quarterly revenue can fluctuate significantly between periods. A quarter-over-quarter (QoQ) change does not always indicate a trend; comparing the same quarter year-over-year (YoY) is a more reliable signal for underlying growth. Universe Pharmaceuticals Inc.'s revenue data from 2018 to 2026 shows full historical quarterly detail on this page.
How is UPC's revenue distributed by segment?
UPC reports revenue broken down by product line and geographic region. The segment breakdown on this page shows which business units contribute the most to total revenue as of the latest fiscal year. Concentration in a single segment above 50% indicates category dependence, while a diversified mix signals more resilient revenue streams.
How does UPC's revenue compare to industry peers?
Universe Pharmaceuticals Inc. (UPC) with TTM revenue of $41M and -14.1% YoY growth can be benchmarked against sector peers using the comparison table on this page. Revenue growth relative to peers indicates market share gains or losses. The peer section shows TTM revenue, YoY growth, and operating margin for direct comparisons.